2 000家美国制药厂在COVID-19之前未接受检查,引起安全问题。 2,000 US pharmaceutical plants not inspected since before COVID-19 raise safety concerns.

美国食品和药物管理局面临着近2000家药厂的大量积压,这些药厂自COVID-19大流行前以来没有进行检查,约占美国注册设施的42%. The FDA is facing a significant backlog of nearly 2,000 pharmaceutical plants that have not been inspected since before the COVID-19 pandemic, representing about 42% of U.S.-registered facilities. 这引起了对包括抗生素和癌症治疗在内的关键药物安全的关切。 This raises concerns over the safety of critical medications, including antibiotics and cancer therapies. 视察在2020年3月基本停止,恢复缓慢,2021年视察人数下降了40%。 Inspections were largely halted in March 2020, resuming slowly, with 2021 seeing a 40% drop in inspection numbers. 美国食品和药物管理局指出, 人员短缺和国际检查局限性是造成这一问题的因素. The FDA cites staffing shortages and international inspection limitations as contributing factors.